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ZNF341 controls STAT3 expression and thereby immunocompetence 
One Sentence Summary 
Homozygous nonsense mutations in ZNF341 impair its ability to activate STAT3 transcription 
and thereby cause immunodeficiency. 
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ABSTRACT 
Signal-transducer-and-activator-of-transcription-3 (STAT3) is a central regulator of immune 
homeostasis. STAT3 levels are strictly controlled and STAT3 impairment contributes to several 
diseases including the monogenic autosomal-dominant hyper-IgE syndrome (AD-HIES). We 
investigated patients of four consanguineous families with an autosomal-recessive disorder 
resembling the phenotype of AD-HIES, with symptoms of immunodeficiency, recurrent 
infections, skeletal abnormalities, and elevated IgE. Patients presented with reduced STAT3 
expression and diminished Th17 cell numbers, in absence of STAT3 mutations. We identified two 
distinct homozygous nonsense mutations in ZNF341, which encodes a zinc-finger transcription 
factor. Wild-type ZNF341 bound to and activated the STAT3 promoter, whereas the mutant 
variants showed impaired transcriptional activation, partly due to nuclear translocation failure. In 
summary, nonsense mutations in ZNF341 account for the STAT3-like phenotype in four 
autosomal-recessive kindreds. Thus, ZNF341 is a previously unrecognized regulator of immune 
homeostasis.  
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INTRODUCTION 
Immune homeostasis in humans is important to avoid the two extremes of immunodeficiency and 
autoimmunity/autoinflammation. Signal-transducer-and-activator-of-transcription-3 (STAT3) is 
an immune rheostat that prevents such diseases by regulating the innate and adaptive immune 
system (1). Th17 CD4
+
 T cell differentiation and IL-17 production are dependent on precisely 
balanced STAT3 activity (2-6), and germline and somatic mutations in STAT3 have been 
associated with multiple immune disorders and cancer, respectively (7). For instance, 
heterozygous germline gain-of-function mutations lead to lymphoproliferation and juvenile-onset 
autoimmunity (8, 9), whereas heterozygous loss-of-function (LOF) mutations in STAT3 cause an 
autosomal-dominant (AD) immunodeficiency known as hyper-IgE syndrome (HIES, OMIM 
#147060 and #243700) (10). STAT3-LOF mutations have been shown to exert a dominant-
negative effect impairing antibacterial and antifungal host defense and resulting in multisystem 
disorder also affecting the skeleton, dentition and connective tissue (11, 12). Patients present with 
the clinical triad of recurrent pneumonia, eczema with cold staphylococcal skin abscesses, and 
elevated serum IgE levels (11). STAT3-LOF mutations represent the underlying genetic defect in 
~75% of sporadic and AD-HIES patients (MIM: 102582), whereas biallelic DOCK8 mutations 
account for disease in ~80% of patients with the autosomal-recessive (AR) form of HIES (MIM: 
611432, (13, 14)). Additionally, mutations in PGM3 (MIM: 172100, (15, 16)) have been 
described in AR-HIES. At least one of these AR immunodeficiency syndromes also involve 
dysregulated STAT3 function since the lack of DOCK8 results in reduced STAT3 activation (17, 
18).  
However, regulatory mechanisms of the STAT3 equilibrium are complex and not fully 
understood. Regulation at protein level includes phosphorylations and interaction with other 
STAT family members (19). In addition, epigenetic regulation by HMGB1 (20) or ZNF382 (21) 
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and transcriptional regulation of STAT3 through STAT3 homodimers and other yet unidentified 
transcription factors have been proposed (22). 
Here, we report that ZNF341, a previously uncharacterized C2H2-zinc finger transcription factor, 
is mutated in families with recurrent bacterial and fungal infections. Two distinct homozygous 
nonsense mutations in exons 6 and 8 of ZNF341 segregate with a phenotype resembling HIES in 
four consanguineous families with AR inheritance. We describe ZNF341 as a positive regulator 
of STAT3 expression and report the clinical and laboratory phenotype of individuals lacking 
ZNF341.  
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RESULTS 
STAT3 HIES-like phenotype with autosomal-recessive inheritance identified in four 
consanguineous families 
We performed mutational analyses to identify the genetic defects in four consanguineous HIES-
families with AR inheritance, in which mutations in known HIES genes had previously been 
excluded. The clinical triad of HIES consisting of recurrent pneumonias, eczema with cold skin 
abscesses, and elevated serum IgE levels was present in all three affected individuals (A.II.1, 
A.II.2 and A.II.3) of the consanguineous Family A (for representative pictures of clinical findings 
see Fig. 1; pedigree of Family A in Fig. 2A). Additionally, they showed skeletal/connective tissue 
abnormalities and formation of bronchiectasis and pneumatoceles (Fig. 1D) characteristic for 
STAT3-HIES and also suffered from recurrent candidiasis. Affected members of Families B, C 
and D (Fig. 2B-D) presented with a milder phenotype initially diagnosed as atopic dermatitis, 
with characteristic HIES symptoms occurring later in life. The three Israeli families (Families A, 
B and C) are descendants from soldiers who lived in Sudan in the 19
th
 century. Family D is of 
Turkish origin. Increased susceptibility to viral infections, typical in DOCK8-deficient AR-HIES, 
was not observed in any of the patients.  
Reduced Th17 CD4
+
 T cell numbers in patients with STAT3 HIES-like phenotype 
Immunophenotyping revealed normal CD19 lymphocyte counts, but an increased percentage of 
naïve B cells (IgD
+
CD27
-
), and reduced memory B cells (CD27
+
) in the affected individuals. All 
memory B cell subpopulations including IgG
+
, IgA
+
 and IgM
+
 were significantly reduced (fig. 
S1A). Patients had normal counts for naïve and memory CD4
+
 and CD8
+
 T cells, and for the 
CD4
+
 subsets Th1, Th1* (CCR6+ Th1 cells), and Th2 (fig. S1B). Patients however presented a 
significantly reduced percentage of Th17 CD4
+
 T cells, a key feature of STAT3-HIES (Fig. 2F, 
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left panel). This coincided with reduced expression of CCR6, which is STAT3-dependent (23), in 
memory CD4 T helper cells (fig. S1B, lower right panel). In addition, peripheral blood 
mononuclear cells (PBMCs) derived from patients failed to differentiate into IL-17 producing 
CD4
+
 T cells (Fig. 2F, right panel, fig. S1C) and showed reduced numbers of IL-22
+
 T cells (fig. 
S1D). Detailed case reports, clinical findings and extended immune phenotyping can be found in 
the Supplementary material (supplements S1 and S2, table S1 and fig. S1). Taken together, these 
findings support the hypothesis that patients with ZNF341 mutations have a previously 
unrecognized autosomal-recessive immunodeficiency that clinically resembles autosomal-
dominant HIES due to mutations in STAT3. 
Homozygous nonsense mutations in ZNF341 causing the disease phenotype in four HIES families 
Genetic defects in STAT3 itself were excluded by sequencing of the exons, cDNA, and the 
genomic promoter region (supplement S3). We therefore performed genetic linkage analysis of 
Family A and subsequent whole exome sequencing (WES) on two patients and one healthy 
sibling of Family A (supplement S4). We identified a homozygous nonsense mutation in exon 6 
of ZNF341 (Chr20:32345116C>T; GRCh37; c.904C>T; p.Arg302*, R302* for isoform1; RefSeq 
NM_001282933.1), which was also present in all patients from Family B and C (Fig. 2A-C + E). 
At that time, the mutation was absent from dbSNP, but it was later listed as rs746141726 with an 
allele frequency of 0.0017% and observed only in the heterozygous state. By targeted next-
generation sequencing, we identified a second homozygous ZNF341 nonsense mutation in exon 8 
(Chr20:32349795C>T; GRCh37; c.1156C>T; p.Arg386*, R386* for isoform1) in Family D, 
which segregated with the disease status (Fig. 2D + E). 
ZNF341 comprises 15 exons and encodes for three isoforms (RefSeq NM_001282933.1; 
NM_032819.4; NM_001282935.1; three additional non-coding variants are listed in Ensembl, 
table S2). Expression of mRNA was confirmed in several cell lines and PBMCs (supplement S5 
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and fig. S2). We focused on the longest isoform 1, a 854 amino acid protein with twelve C2H2 
zinc finger domains but no other conserved domain (Fig. 2G) and with putative transcription 
factor activity (UniProt: Q9BYN7-1 and GO annotation). Both identified mutations predict 
premature termination of translation, deleting eleven (p.Arg302*; 31.1 kDa) or nine (p.Arg386*; 
40.4 kDa) C2H2 zinc finger domains, respectively. As expected, full length ZNF341 isoform 1 
was absent in patient-derived (B.II.1, B.II.4, D.II.2, D.II.4) EBV transformed B cell lines (Fig. 
3A, upper panel). 
Although the patients presented with high IgE levels, a review of the atopic-dermatitis-meta-
analysis of the EAGLE consortium of 10,788 atopic dermatitis cases and 30,047 controls (24) did 
not reveal any significantly associated variant after Bonferroni correction within locus 20q11.22 
(ZNF341 ± 200kb) (fig. S3). In addition, this locus was not reported in a published GWAS meta-
analysis of allergic sensitization in 11,903 affected cases and 19,976 controls (25), and no 
associated variants within this locus are listed in the current version of the NHGRI GWAS 
Catalog (www.ebi.ac.uk/gwas)(26) for atopy-related traits such as asthma, rhinitis, atopic 
dermatitis, and allergic sensitization.  
Reduced STAT3 mRNA and protein in patients with homozygous ZNF341 nonsense mutations 
To identify potential target genes of the ZNF341 transcription factor, we compared the 
transcriptomes of PBMCs derived from patient A.II.1 and his healthy sister A.II.5 (table S3), and 
confirmed the observations by RT-qPCR for additional individuals. ZNF341 mRNA expression 
was variable and slightly increased in patients (A.II.1, A.II.2, A.II.3, D.II.4), compared to healthy 
controls (Fig. 3A, lower panel). However, STAT3 mRNA expression was significantly reduced in 
PBMCs of all affected individuals (A.II.1, A.II.2, A.II.3 and D.II.4) compared to healthy controls 
(Fig. 3B, left panel). 
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These findings suggest that the STAT3-like HIES phenotype caused by ZNF341 mutations could 
be associated with insufficient STAT3 expression, presenting a previously unrecognized 
pathogenesis in addition to the well-described dominant-negative effect usually associated with 
STAT3 mutations. Reduced STAT3 mRNA expression was also observed in an EBV-transformed 
B cell line of patient A.II.1, in a HVS-transformed T cell line of patient A.II.3, and in primary 
skin fibroblasts (PSF) of patient A.II.3 (Fig. 3B). Moreover, STAT3 protein expression was 
reduced in ZNF341-mutant cells (patients’ PBMCs, EBV-transformed B cells, and PSF) down to 
15.5-27% of wild-type levels (Fig. 3C). Along the same lines, knockout of ZNF341 in Ramos B 
cells by CRISPR/Cas9 technology, showed reduced STAT3 protein expression (Fig. 3D). 
Furthermore, STAT3 Y705-phosphorylation was markedly impaired in PBMCs from patients 
with R302* and R386* mutations, respectively, following stimulation with IL-6 (Fig. 4A), or 
with IFN-α in EBV cells from patient A.II.1 (Fig. 4B, left panel). Impaired STAT3 Y705-
phosphorylation upon stimulation was even more obvious in EBV cell lines from two patients 
(B.II.1 and B.II.4) (Fig.4B right panel), indicating that reduced total STAT3 levels consequently 
lead to overall reduced phospho-STAT3 levels. As we had excluded genetic defects in STAT3 
itself, we conclude that the mutations in ZNF341 account for the HIES-phenotype due to the 
incapability of mutant cells to increase STAT3 protein expression and STAT3 phosphorylation 
above basal levels, leading to an imbalanced STAT3/phospho-STAT3 ratio in affected 
individuals.  
Binding of ZNF341 to the STAT3 promoter and subsequent activation of transcription 
We next confirmed the transcriptional activation of the endogenous STAT3 promoter upon 
transient overexpression of GFP-fused ZNF341 in HEK293T cells (fig. S4). In contrast to the 
R302*-mutant, wild-type ZNF341 caused a two-fold increase of STAT3 mRNA expression (fig. 
S4A). Using fluorescence-based reporter assays with synthetic promoters, composed of a 
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genomic STAT3 fragment (-535/-33 relative to the transcription start) fused to the CMV minimal 
promoter, we observed an average 2.9 -fold increase of reporter expression over basal activity 
upon co-transfection with wild-type ZNF341, whereas only marginal activation (average 1.4-
fold) was observed with the R302*-mutant ZNF341 after 48 hours (Fig. 5A+B). Increased 
reporter activity (average 2.6-fold) was also observed with the overexpressed ZNF341 variant 
R386* (which yielded much higher expression levels than the wild-type protein (fig. S4C)), 
suggesting that residual transcription factor activity is retained (Fig. 5A+B). Similar results were 
obtained with longer (-997/-33) and shorter (-476/-33) STAT3 promoter fragments and at variable 
time points (fig. S5).  
To determine whether ZNF341 directly regulates STAT3 by binding to its promoter, we searched 
for ZNF341 binding sites by ChIP-Seq. ChIP-Seq data, obtained with two different antibodies 
recognizing ZNF341, were highly correlated (fig. S6A). We identified 1,658 high-confidence 
ZNF341 binding sites genome-wide, with a high proportion being located at promoters or within 
short distance to promoters (< 1 kb) (Fig. 5C). The STAT3 promoter displayed high ZNF341 
occupancy (Fig. 5D), which was confirmed by ChIP (fig. S6B). This was not observed in patient-
derived cells, highlighting the specificity of the antibody as well (fig. S6C). Thirty-six binding 
sites, termed super-binding sites, were characterized by high level of ZNF341 occupancy (Fig. 
5E) and accounted for approximately half of ZNF341 occupancy (as determined by normalized 
tag count) (Fig. 5F). Expression of the genes associated with the top two binding sites (STAT3 
and KAT6A) was decreased in patient-derived PBMCs compared to a healthy control, further 
supporting the role of ZNF341 as a transcriptional activator (table S3). To identify the sequence 
recognized by ZNF341, we performed de novo motif analysis. A 10-nt motif was highly enriched 
at ZNF341 binding sites, as well as a separate 10-nt G-rich motif (Fig. 5G). When searching for 
longer motifs, we identified a 30-nt sequence, which contained both 10-nt motifs (Fig. 5H, top 
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panel), located at position -217/-187 in the STAT3 promoter region (relative to the transcription 
start). This motif could be further refined in the super-binding sites (Fig. 5H, lower panel), 
suggesting that ZNF341 utilizes several zinc fingers for DNA binding, whereas the remaining 
zinc fingers may contribute to preferential binding. This might explain why half of ZNF341 
occupancy occurs at only 36 preferential binding sites. Thus, ZNF341 has the potential to 
recognize a highly specific sequence and therefore to regulate a limited number of genes, 
including STAT3.  
Aberrant cytoplasmic localization of nuclear ZNF341 caused by the R302* mutation 
We further characterized the molecular defects of the ZNF341 nonsense mutations by transient 
overexpression in HEK293T cells (fig. S4). The wild-type ZNF341 achieved moderate protein 
levels (regardless of whether fused to EGFP or not) whereas both truncated proteins (R302* and 
R386*) were expressed at higher levels (fig. S4B+C; for expression levels see also fig. S5B, 
S7C+D). Confocal microscopy (Fig. 5I) of EGFP-fused constructs showed that the wild-type 
ZNF341 localized to the nucleus, as predicted by the protein atlas. In contrast, truncated EGFP-
ZNF341-R302* remained in the cytoplasm, indicating that the nuclear localization sequence 
(NLS) was deleted. Thus, the inability of the R302* mutant to contribute to transcriptional 
activation is most likely due to the failure of nuclear translocation and accordingly we did not 
detect any binding of ZNF341 variant R302* to chromatin (fig. S6C, S7A+B). Surprisingly, the 
truncated mutant EGFP-ZNF341-R386* retained its ability to localize to the nucleus (Fig. 5I). 
Thus, a potential NLS, which is predicted to reside between K299 and Y326 (http://nls-
mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi), is sufficient for nuclear translocation of 
ZNF341-R386*. Nevertheless, the ZNF341-R386* variant showed reduced binding to chromatin 
in an overexpression system (fig. S7A+B). Because ZNF341-R386* lacks nine of the twelve zinc 
finger domains, residual transcription factor activity may occur only upon massive 
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overexpression in vitro. The clinical phenotype however, suggests that the three remaining zinc 
fingers are insufficient for ZNF341-R386* binding to and activation of target promoters at 
physiological levels.   
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DISCUSSION 
JAK-STAT signaling pathways have emerged as critical rheostats for the maintenance of cellular 
homeostasis, relevant to many human diseases (27-29). Impaired JAK-STAT signaling either 
causes immunodeficiency if decreased (30-32) or lymphoproliferative disorders, if increased (8, 
9, 33). Hence, the regulation of the amount of STAT (and JAK) signaling molecules and their 
phosphorylation status seem to determine the outcome of cellular signaling events. For example 
LOF mutations in STAT1 lead to susceptibility to viral and mycobacterial infections (34, 35), 
whereas GOF mutations in the very same gene lead to a polarization of T lymphocytes away 
from the Th17 CD4
+
 T cell lineage towards the Th1 lineage, leading to an increased susceptibility 
to recurrent fungal infections (36-38). 
Furthermore, decreased STAT3 signaling, due to dominant-negative mutations (10, 12), leads to 
immunodeficiency characterized by the loss of Th17 CD4
+
 T cells (3-5). In contrast, somatic 
GOF mutations in STAT3 lead to large-granular-lymphocytosis (39), and germline GOF 
mutations in STAT3 lead to a complex immune-dysregulation syndrome (8, 9). Therefore, the 
mechanisms controlling these cellular regulators (i.e., the transcription factors of the JAK and 
STAT molecules) become of central importance in human disease. JAK- and STAT-inhibitors 
have already been used to treat lymphoma/cancer, autoimmune diseases such as rheumatoid 
arthritis (40), and impaired infection control (41, 42). 
Here, we describe a transcription factor regulating transcription of STAT3: ZNF341. As in HIES 
patients with STAT3 LOF mutations, the impairment of ZNF341 signaling also led to defective 
differentiation of naïve T cells into Th17 cells (and hence IL-17 production), a process critically 
dependent on STAT3. Thus, we discovered that ZNF341 transcriptionally regulates STAT3 
expression, at least its increase above a certain basal level of transcription, but other aspects of 
the underlying mechanism of impaired JAK-STAT signaling due to homozygous nonsense 
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mutations in ZNF341 still need to be elucidated. While reduction of ZNF341 reduces expression 
of STAT3, there may be more complex regulatory mechanisms involved, which await further 
elucidation. Likewise, whether the phenotype results mainly/exclusively from disrupted STAT3 
levels or also from the dysregulation of other genes by mutant ZNF341, remains unclear. 
Although the mutated proteins can be expressed in an overexpression system, in patient cells 
mutated proteins escaped our detection by the available antibodies. With the development of 
more specific N-terminal antibodies, however, the question of retained translation of a mutated 
shortened ZNF341 in patients will be solved. This will be important to clarify the issue whether 
the R386* mutation disturbs transcriptional activity of ZNF341 by inexpressibility or nonsense-
mediated decay of the truncated protein, or by other mechanisms affecting nuclear transcription. 
Moreover, homo- or hetero-dimerization of ZNF341 was not investigated. 
Although our patients presented with high IgE levels, to date, ZNF341 has not been associated 
with atopy related traits such as asthma, rhinitis, atopic dermatitis, and allergic sensitization (43-
45). As ZNF341 comprises 12 zinc fingers, and as one zinc finger shows preference to a specific 
nucleotide triplet (46), ZNF341 has the potential to recognize a very specific sequence and 
regulate a limited number of genes, which is supported by the super-binding sites and motif 
analysis. In this regard, KAT6A, the gene whose promoter has the second top-binding site by 
ChIP, was down-regulated in the transcriptome analysis (table S3). Interestingly, mutations in 
KAT6A were recently identified in patients presenting with neurodevelopmental disorders (47). 
Lower KAT6A expression may contribute to the intellectual disabilities observed in our patients. 
Our data show that ZNF341 acts as a transcriptional activator for cytokine-mediated STAT3 
expression. Zinc finger transcription factors lacking other functional domains have been 
described to recruit either transcriptional activators or repressors or both (48). Overexpressed 
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ZNF341 has been described to bind to PAF1, which plays a role in transcriptional elongation 
(48), supporting a role for ZNF341 as a transcriptional activator.  
In summary, the transcription factor ZNF341 is a positive regulator of STAT3 expression. 
Homozygous nonsense mutations in ZNF341 lead to insufficient STAT3 levels, which prevent 
Th17 cell differentiation and cause HIES-like phenotypes with recurrent infections. Thus, the 
well-known HIES phenotype is not only associated with well-described dominant-negative 
STAT3 mutations, but can also result from insufficient levels of otherwise normal STAT3.  
Our observations also have pivotal importance regarding future intervention strategies in STAT3-
dependent HIES. Since HIES can be caused by STAT3 insufficiency, gene therapeutic attempts 
aiming at the inactivation of the mutant allele to eliminate dominant-negative STAT3 mutations, 
should be carefully considered. On the other hand, treating STAT3-insufficient cells with 
recombinant ZNF341 might improve infection control. An interesting aspect in future research 
will be the link between ZNF341 and the maintenance of normal IgE levels, particularly in the 
context of allergy. Our patients with ZNF341 deficiency had highly elevated serum IgE levels. 
Hence, augmentation of ZNF341 function may normalize IgE production, possibly by interfering 
with Th2 cell subset differentiation.  
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MATERIALS AND METHODS 
Study Design 
The aim of this study was to characterize the underlying genetic defect and pathomechanism in a 
consanguineous AR-HIES family without mutations in known HIES genes. After the 
identification of ZNF341 (encoding a transcription factor regulating STAT3) as the disease-
causing gene in Family A, additional families with unexplained AR-HIES were tested for 
ZNF341 mutations.  
Patients and Controls 
The study was conducted under protocols for human subjects. Samples were collected with the 
written consent of all study participants and/or their parental guardians after formal ethical 
approval by the local ethics committees at the University of Freiburg (ethics protocol numbers 
239/99_120733 and 302/13), the Rambam Medical Center, the Children´s Medical Center of 
Israel, Uludag University Medical Faculty, and collaborating institutions. Healthy family 
members were sequenced for the ZNF341 mutation and wt/wt family members were included 
into the healthy donor (HD) control group. 
Sample preparation 
Human PBMCs were isolated by Ficoll density gradient centrifugation and either immediately 
used or frozen and stored in liquid nitrogen. Epstein-Barr virus (EBV) transformed lymphoblastic 
B cell lines and Herpesvirus saimiri immortalized T- cell lines (HVS-T) were generated from 
PBMCs by standard methods. Primary skin fibroblasts (PSF) were generated from a skin biopsy 
of patient A.II.3 by standard methods and healthy donor PSF were kindly provided by AG 
Finkenzeller. 
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Flow cytometry  
Immunophenotyping of PBMCs was performed by staining for various cell surface markers. A 
list of the fluorochrome-conjugated antibodies and the applied gating strategy can be found in 
supplement S7.  
STAT3 phosphorylation 
For analysis of STAT3 expression and STAT3 phosphorylation, PBMCs were used either 
unstimulated or stimulated with human recombinant IL-6 (0.5µg/ml, PeproTech, Hamburg, 
Germany) for 15 min at 37°C. EBV-transformed B cell lines were stimulated with IFN-α 
(0.5µg/ml, PeproTech, Hamburg, Germany) for 5, 15, 60 and 150 min at 37°C. Cells were fixed 
(Lyse/Fix buffer, BD Biosciences) and permeabilized (Fix/Perm III buffer, BD Biosciences) 
according to the manufacturer´s instructions. Cells were stained with anti-STAT3-FITC (clone 
#232209; R&D Systems Wiesbaden-Nordenstadt, Germany), anti CD19 BV421 (clone HIB19, 
Biolegend), or with phospho-specific PE-coupled anti-STAT3 (pY705) antibodies (clone 4/P-
STAT3, BD Biosciences), CD3-FITC (clone SK7, BD Bioscience). Fixable viability dye eFluor 
506 (eBioscience, Frankfurt, Germany) was used according to the manufacturer´s instructions.  
In vitro Th17 cell differentiation 
For in vitro differentiation assays, freshly purified PBMCs were stimulated with anti-CD2, anti-
CD3 and anti-CD28 coated beads, using a T cell activation/expansion kit according to the 
manufacturer´s instructions (Miltenyi Biotec, Bergisch Gladbach, Germany), in combination with 
IL-1ß (10ng/ml) and IL-6 (50ng/ml) or TGF-beta (5ng/ml) and IL-21 (25ng/ml) for four days. 
Prior to and after induction, cells were stimulated for 4 hours with 50ng/ml PMA and 1µg/ml 
ionomycin (both from Sigma) in the presence of 5µg/ml Brefeldin A (BD Biosciences). Cells 
were stained for surface markers with anti-CD4 PercP-Cy5.5 (clone RPTA-T4, BD Biosciences), 
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anti-CD45RO PE-Cy7 (clone UCHL1, ebiosciences) and anti-CD3 APC H7 (clone SK7, BD 
Bioscience), fixed and permeabilized using Cytofix kit (BD Biosciences). For intracellular 
staining anti-IFN-γ FITC (Clone B27, BD Biosciences) and anti-IL-17 PE (Clone eBio64DEC17, 
eBioscience) were used. Fixable viability dye eFluor 506 (eBioscience, Frankfurt, Germany) was 
used according to the manufacturer´s instructions. 
All flow cytometry data was acquired on a FACS-Canto II flow cytometer (BD Biosciences) and 
analyzed using FlowJo version X analysis software (Treestar, Ashland, OR).  
RNA isolation, cDNA generation, quantitative PCR and cDNA sequencing 
Total RNA, either from PBMCs, EBV cell lines, HVS transformed T cell lines, PSF, HEK293T 
cells or further cell lines, was isolated with the RNeasy Mini Kit using QIAshredder and column 
DNA digestion (Qiagen). cDNA was synthesized with QuantiTect reverse transcription kit 
(Qiagen). qPCR was performed in duplicates or triplicates using SYBR Green reagents (Qiagen 
or Thermo Scientific) and primers for STAT3, ZNF341 and for the house-keeping gene GUSB. 
Fluorescence intensities were monitored over 40 cycles on a StepOne real-time PCR system 
(Applied Biosystems/Thermo Fisher Scientific) and relative mRNA expression was calculated 
with the 2
-ΔΔCt
 method. The STAT3 cDNA sequences were analyzed using long range PCRs with 
Q5 High-Fidelity DNA Polymerase (NEB) and Sanger sequencing. The most important primer 
sequences can be found at the end of Supplemental methods and all primer sequences are 
available upon request. 
Western blotting  
Fresh or frozen PBMCs, EBV transformed B cells, PSF, or transfected HEK293T lysates were 
used for blotting. Membranes were probed with primary antibodies separately for STAT3 
(MAB1799; R&D Systems), ZNF341 (polyclonal: Atlas Antibody HPA024607 or monoclonal: 
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customized antibody), GAPDH (G9295; Sigma), or beta-actin (NB 600-532; Novus Biologicals). 
A detailed protocol can be found in supplement S7.  
CRISPR/Cas9-mediated genome editing 
ZNF341 knock-out cells were generated using CRISPR/Cas9 technology. A guide RNA (gRNA) 
with high target specificity was selected using the CRISPR design tool from MIT 
(http://crispr.mit.edu). The gRNA (CGTCGGGTCTTCAGCGTTGC) was targeting a region 
close to R302 and was cloned in the pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid, a gift from 
Feng Zhang (Addgene plasmid #42230). ZNF341
−/−
 clones were generated by single cell sorting 
of EGFP-positive RAMOS cells co-transfected with pX330-ZNF341-gRNA and a EGFP plasmid 
(1:10 ratio) in 96-wells plates. After about three weeks, clones were screened by Western Blot 
analysis. 
Expression vectors and fluorescence-based promoter-reporter assay  
The cDNAs for isoform 1 of wild-type ZNF341 and mutant ZNF341-R302* were cloned from 
patient derived samples by RT-PCR. Mutant ZNF341-R386* was generated by site-directed 
mutagenesis. For transient transfection in HEK293T cells, expression vectors for EGFP-fused or 
non-fused versions were used (pEGFP-C1 and –N1; Takara/Clontech) with the empty vectors as 
controls. Cells were transfected with XtremeGeneHP reagent (Roche) and harvested 48 h post 
transfection for RNA or protein analyses. 
For the fluorescence-based promoter-reporter assay, three genomic fragments of the human 
STAT3 promoter, comprising the upstream sequence from -997 to-33, from -535 to -33 or from -
476 to -33 relative to the putative transcription start site (49), were amplified by PCR and fused 
to a 58 bp CMV minimal promoter (without specific transcription factor binding sites). The 
synthetic promoter constructs provide a TATA box and an artificial transcription start site and 
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drive the expression of a red fluorescent tdTomato reporter protein (Takara/Clontech). 
Expression vectors for non-fused or EGFP-fused wild-type ZNF341, mutant ZNF341-R302*, or 
mutant ZNF341-R386*, respectively, were co-transfected with the reporter into HEK293T cells 
using XtremeGeneHP (Roche) transfection reagent. The empty vector pEGFP-C1 (without 
ZNF341 cDNA) was used as control. Reporter assays (n=4) were performed in 48 well plates in 
quadruplets and evaluated with a Fluorospot reader at variable time points (48h/72h/96h; 
repeated measurements per plate at two distinct time points each). Reporter constructs containing 
only the CMV minimal promoter (without STAT3 upstream sequences) and RORC- and IL17A- 
promoter constructs (both fused to CMVmin) were confirmed to be non-activatable by ZNF341 
in independent experiments. Cells were analyzed for green (expression and subcellular 
localization of GFP-fused ZNF341) and red fluorescence (reporter activity) by conventional epi-
fluorescence microscopy on a Zeiss Axiovert 200. Images were processed using the Zen software 
(Zeiss). Fluorescence intensities were measured on a Fluorospot analyzer (CTL, Bonn Germany) 
and quantified using ImageJ software. 
ChIP and ChIP-Seq  
Cells were fixed for 15 minutes in 1% formaldehyde in PBS with 2% FCS. Formaldehyde was 
quenched for 10 minutes with 0.2M glycine. Cells were washed 2 times with ice-cold PBS. 30µl 
Protein G Dynabeads (Life Technologies) were blocked with 0.5% BSA (w/v) in PBS. Magnetic 
beads were bound with 5µg of anti-ZNF341 antibody (polyclonal: Atlas Antibodies HPA024607 
or monoclonal: customized antibody) or control rabbit IgG (Santa Cruz Biotechnology sc2027x). 
Crosslinked cells were lysed in lysis buffer (0.5% NP-40, 10mM HEPES, 85mM KCl, 4ul 
EDTA). After centrifugation, nuclei were resuspended and sonicated in sonication buffer (50mM 
Tris-HCl pH8.0, 1% SDS, 10mM EDTA) for 5 cycles at 10 sec each on ice (20W) with 50 sec on 
ice between cycles. Lysates were cleared by centrifugation and Triton X-100 was added at a final 
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concentration of 1%. Lysates were then incubated overnight at 4°C with the previously prepared 
magnetic beads. Beads were washed once with RIPA (50mM Tris-HCl pH8.0, 150mM NaCl, 
0.1% SDS, 0.1% Na-Deoxycholate, 1% Triton X-100, 1mM EDTA), once with RIPA 500 
(50mM Tris-HCl pH8.0, 500mM NaCl, 0.1% SDS, 0.1% Na-Deoxycholate, 1% Triton X-100, 
1mM EDTA), once with LiCl wash (10mM Tris-HCl pH8.0, 250mM LiCl, 0.5% NP-40, 0.5% 
Na-deoxycholate, 1mM EDTA) and finally twice with TE (10mM Tris pH8.0, 1mM EDTA). 
Bound complexes were eluted from the beads in elution buffer (10mM Tris-HCl pH8.0, 0.5% 
SDS, 300mM NaCl, 5mM EDTA) for 30 min at 65 °C with shaking. Crosslinks were reversed 
overnight at 65°C. RNA and protein were digested in the supernatant using RNase A and 
Proteinase K. DNA was purified using ChIP DNA clean and concentrator columns 
(Zymoresearch). ChIP primers are listed in supplement S6. ChIP results are represented as 
percent of input by dividing the signals obtained by the ChIP by the signals obtained from the 
input sample. For ChIP-Seq, libraries were prepared with the NEBNext primer set and were size-
selected with AMPure XP beads (Beckman Coulter). Libraries were run on Illumina HiSeq 2000. 
Reads were aligned to hg19 using Bowtie with the parameter –m 1 (http://bowtie-
bio.sourceforge.net). Data were analyzed using HOMER (http://homer.salk.edu/homer). To 
correlate ChIP-Seq data obtained with monoclonal and polyclonal antibodies, peaks were 
identified using the findPeaks command in the combined tag directory and annotated with each 
tag directory using the –log option. A Pearson correlation test was applied to identify correlation 
between the tag counts. High-confidence peaks were identified using the 
getDifferentialPeaksReplicates.pl command using the ChIP-Seq data obtained with the two 
antibodies as replicates. Motifs of 8, 10 or 12-nt were identified using the findMotifsGenome.pl 
command with parameter –cpg in a window of 100 bp (-size 100). Longer motifs were identified 
by searching for motifs of lengths more than 15-nt and top motif was identified using a length of 
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30 (-len 30). Optimization of the long motif in the super-binding sites was performed with 
parameter –opt.  
Statistical analysis  
Data (not including genetic linkage analysis, transcriptome study and motif analysis) were 
analyzed with the GraphPad InStat software program, version 6, by using nonparametric Mann-
Whitney tests. Differences were considered significant at a P value of less than 0.05. 
Detailed protocols for Genetic linkage analysis, Whole exome sequencing (WES), Next 
Generation Sequencing (NGS), Sanger sequencing, CGH Array, and Transcriptome study can be 
found in Supplementary material and methods (S6).  
23 
LIST OF SUPPLEMENTARY MATERIALS  
Supplement S1. Case reports for Families A-D. 
Supplement S2. Defective B cell development and Th17 cell differentiation in HIES patients 
with ZNF341 nonsense mutations. 
Supplement S3. Exclusion of mutations in STAT3 in the etiology of the HIES phenotype in 
Family A. 
Supplement S4. Identification of ZNF341 as an AR-HIES-associated gene in a linkage region on 
chromosome 20 by whole exome sequencing. 
Supplement S5. Expression of various ZNF341 mRNA variants in multiple cell lines and 
PBMCs. 
Supplement S6. Supplementary materials and methods 
Fig. S1. B and T cell subsets in patient-derived and healthy donor PBMCs. 
Fig. S2. Ubiquitous expression of ZNF341 mRNA in various cell types. 
Fig. S3. No association of the genomic region 20q11.22 spanning the ZNF341 locus with atopy. 
Fig. S4. Ectopic expression of ZNF341 variants in HEK293T cells. 
Fig. S5. Ectopically expressed wild-type ZNF341 binds to the STAT3 promoter leading to 
transcriptional activation. 
Fig. S6. Occupancy by ZNF341 across the STAT3 promoter as determined by ChIP. 
Fig. S7. ZNF341 R386* shows reduced binding to the STAT3 promoter. 
Fig. S8. Flow cytometry gating strategy for in vitro Th17 cell differentiation assay. 
Fig. S9. Flow cytometry gating strategy for Y705-phosphorylation of STAT3. 
Fig. S10. Flow cytometry gating strategy for immune phenotyping of PBMCs. 
Fig. S11. Flow cytometry gating strategy for IL22
+
 T cells. 
24 
Table S1. Clinical and immunological phenotype of HIES patients with ZNF341 mutations. 
Table S2. ZNF341 encodes three protein coding isoforms.  
Table S3. Transcriptome Analysis of patient A.II.1 with gene-specific fold changes in 
comparison to healthy sibling A.II.5. 
Table S4. Raw data.  
25 
REFERENCES AND NOTES  
1. E. J. Hillmer, H. Zhang, H. S. Li, S. S. Watowich, STAT3 signaling in immunity. 
Cytokine & growth factor reviews 31, 1 (Oct, 2016). 
2. S. Al Khatib et al., Defects along the T(H)17 differentiation pathway underlie genetically 
distinct forms of the hyper IgE syndrome. The Journal of allergy and clinical immunology 
124, 342 (Aug, 2009). 
3. L. de Beaucoudrey et al., Mutations in STAT3 and IL12RB1 impair the development of 
human IL-17-producing T cells. The Journal of experimental medicine 205, 1543 (Jul 7, 
2008). 
4. C. S. Ma et al., Deficiency of Th17 cells in hyper IgE syndrome due to mutations in 
STAT3. The Journal of experimental medicine 205, 1551 (Jul 7, 2008). 
5. J. D. Milner et al., Impaired T(H)17 cell differentiation in subjects with autosomal 
dominant hyper-IgE syndrome. Nature 452, 773 (Apr 10, 2008). 
6. E. D. Renner et al., Novel signal transducer and activator of transcription 3 (STAT3) 
mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation 
in hyper-IgE syndrome. The Journal of allergy and clinical immunology 122, 181 (Jul, 
2008). 
7. P. F. Yong et al., An update on the hyper-IgE syndromes. Arthritis research & therapy 
14, 228 (2012). 
8. S. E. Flanagan et al., Activating germline mutations in STAT3 cause early-onset multi-
organ autoimmune disease. Nature genetics 46, 812 (Aug, 2014). 
9. J. D. Milner et al., Early-onset lymphoproliferation and autoimmunity caused by germline 
STAT3 gain-of-function mutations. Blood 125, 591 (Jan 22, 2015). 
26 
10. S. M. Holland et al., STAT3 mutations in the hyper-IgE syndrome. The New England 
journal of medicine 357, 1608 (Oct 18, 2007). 
11. B. Grimbacher et al., Hyper-IgE syndrome with recurrent infections--an autosomal 
dominant multisystem disorder. The New England journal of medicine 340, 692 (Mar 4, 
1999). 
12. Y. Minegishi et al., Dominant-negative mutations in the DNA-binding domain of STAT3 
cause hyper-IgE syndrome. Nature 448, 1058 (Aug 30, 2007). 
13. K. R. Engelhardt et al., Large deletions and point mutations involving the dedicator of 
cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. The 
Journal of allergy and clinical immunology 124, 1289 (Dec, 2009). 
14. Q. Zhang et al., Combined immunodeficiency associated with DOCK8 mutations. The 
New England journal of medicine 361, 2046 (Nov 19, 2009). 
15. A. Sassi et al., Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) 
impair immunity and increase serum IgE levels. The Journal of allergy and clinical 
immunology 133, 1410 (May, 2014). 
16. Y. Zhang et al., Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link 
glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive 
impairment. The Journal of allergy and clinical immunology 133, 1400 (May, 2014). 
17. S. Keles et al., Dedicator of cytokinesis 8 regulates signal transducer and activator of 
transcription 3 activation and promotes TH17 cell differentiation. The Journal of allergy 
and clinical immunology,  (May 24, 2016). 
18. C. S. Ma et al., Functional STAT3 deficiency compromises the generation of human T 
follicular helper cells. Blood 119, 3997 (Apr 26, 2012). 
27 
19. K. Shuai, B. Liu, Regulation of JAK-STAT signalling in the immune system. Nature 
reviews. Immunology 3, 900 (Nov, 2003). 
20. Y. J. Xu et al., Role of HMGB1 in regulation of STAT3 expression in CD4(+) T cells 
from patients with aGVHD after allogeneic hematopoietic stem cell transplantation. 
Clinical immunology 161, 278 (Dec, 2015). 
21. Y. Cheng et al., KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor 
that represses multiple oncogenes and is commonly silenced in multiple carcinomas. 
Cancer research 70, 6516 (Aug 15, 2010). 
22. L. Lin et al., Transcriptional regulation of STAT3 by SPTBN1 and SMAD3 in HCC 
through cAMP-response element-binding proteins ATF3 and CREB2. Carcinogenesis 35, 
2393 (Nov, 2014). 
23. M. A. Kluger et al., Treg17 cells are programmed by Stat3 to suppress Th17 responses in 
systemic lupus. Kidney international 89, 158 (Jan, 2016). 
24. L. Paternoster et al., Multi-ancestry genome-wide association study of 21,000 cases and 
95,000 controls identifies new risk loci for atopic dermatitis. Nature genetics 47, 1449 
(Dec, 2015). 
25. K. Bonnelykke et al., Meta-analysis of genome-wide association studies identifies ten loci 
influencing allergic sensitization. Nature genetics 45, 902 (Aug, 2013). 
26. D. Welter et al., The NHGRI GWAS Catalog, a curated resource of SNP-trait 
associations. Nucleic acids research 42, D1001 (Jan, 2014). 
27. W. J. Leonard, J. J. O'Shea, Jaks and STATs: biological implications. Annual review of 
immunology 16, 293 (1998). 
28. D. E. Levy, J. E. Darnell, Jr., Stats: transcriptional control and biological impact. Nature 
reviews. Molecular cell biology 3, 651 (Sep, 2002). 
28 
29. A. V. Villarino, Y. Kanno, J. J. O'Shea, Mechanisms and consequences of Jak-STAT 
signaling in the immune system. Nature immunology 18, 374 (Mar 22, 2017). 
30. J. L. Casanova, S. M. Holland, L. D. Notarangelo, Inborn errors of human JAKs and 
STATs. Immunity 36, 515 (Apr 20, 2012). 
31. K. Ghoreschi, A. Laurence, J. J. O'Shea, Janus kinases in immune cell signaling. 
Immunological reviews 228, 273 (Mar, 2009). 
32. W. Vainchenker, A. Dusa, S. N. Constantinescu, JAKs in pathology: role of Janus kinases 
in hematopoietic malignancies and immunodeficiencies. Seminars in cell & 
developmental biology 19, 385 (Aug, 2008). 
33. L. Liu et al., Gain-of-function human STAT1 mutations impair IL-17 immunity and 
underlie chronic mucocutaneous candidiasis. The Journal of experimental medicine 208, 
1635 (Aug 1, 2011). 
34. D. Averbuch, A. Chapgier, S. Boisson-Dupuis, J. L. Casanova, D. Engelhard, The clinical 
spectrum of patients with deficiency of Signal Transducer and Activator of Transcription-
1. The Pediatric infectious disease journal 30, 352 (Apr, 2011). 
35. S. Boisson-Dupuis et al., Inborn errors of human STAT1: allelic heterogeneity governs 
the diversity of immunological and infectious phenotypes. Current opinion in 
immunology 24, 364 (Aug, 2012). 
36. S. Baris et al., Severe Early-Onset Combined Immunodeficiency due to Heterozygous 
Gain-of-Function Mutations in STAT1. Journal of clinical immunology 36, 641 (Oct, 
2016). 
37. F. Dhalla et al., Chronic mucocutaneous candidiasis: characterization of a family with 
STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of 
diagnostic utility. Clinical and experimental immunology 184, 216 (May, 2016). 
29 
38. J. Toubiana et al., Heterozygous STAT1 gain-of-function mutations underlie an 
unexpectedly broad clinical phenotype. Blood 127, 3154 (Jun 23, 2016). 
39. H. L. Koskela et al., Somatic STAT3 mutations in large granular lymphocytic leukemia. 
The New England journal of medicine 366, 1905 (May 17, 2012). 
40. D. M. Schwartz, M. Bonelli, M. Gadina, J. J. O'Shea, Type I/II cytokines, JAKs, and new 
strategies for treating autoimmune diseases. Nature reviews. Rheumatology 12, 25 (Jan, 
2016). 
41. E. Higgins et al., Use of ruxolitinib to successfully treat chronic mucocutaneous 
candidiasis caused by gain-of-function signal transducer and activator of transcription 1 
(STAT1) mutation. The Journal of allergy and clinical immunology 135, 551 (Feb, 2015). 
42. R. Mossner et al., Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic 
Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America 
62, 951 (Apr 1, 2016). 
43. K. Bonnelykke et al., Meta-analysis of genome-wide association studies identifies ten loci 
influencing allergic sensitization. Nature genetics 45, 902 (Aug, 2013). 
44. L. Paternoster et al., Multi-ancestry genome-wide association study of 21,000 cases and 
95,000 controls identifies new risk loci for atopic dermatitis. Nature genetics 47, 1449 
(Dec, 2015). 
45. D. Welter et al., The NHGRI GWAS Catalog, a curated resource of SNP-trait 
associations. Nucleic acids research 42, D1001 (Jan, 2014). 
46. A. Klug, The discovery of zinc fingers and their applications in gene regulation and 
genome manipulation. Annual review of biochemistry 79, 213 (2010). 
30 
47. F. Millan et al., Whole exome sequencing reveals de novo pathogenic variants in KAT6A 
as a cause of a neurodevelopmental disorder. American journal of medical genetics. Part 
A 170, 1791 (Jul, 2016). 
48. F. W. Schmitges et al., Multiparameter functional diversity of human C2H2 zinc finger 
proteins. Genome research 26, 1742 (Dec, 2016). 
49. K. Kato et al., Structure and functional analysis of the human STAT3 gene promoter: 
alteration of chromatin structure as a possible mechanism for the upregulation in 
cisplatin-resistant cells. Biochimica et biophysica acta 1493, 91 (Sep 7, 2000). 
50. B. Grimbacher et al., Genetic linkage of hyper-IgE syndrome to chromosome 4. American 
journal of human genetics 65, 735 (Sep, 1999). 
51. C. Speckmann et al., Reduced memory B cells in patients with hyper IgE syndrome. 
Clinical immunology 129, 448 (Dec, 2008). 
52. A. Finck et al., Linkage of autosomal-dominant common variable immunodeficiency to 
chromosome 4q. European journal of human genetics : EJHG 14, 867 (Jul, 2006). 
53. G. Lopez-Herrera et al., Deleterious mutations in LRBA are associated with a syndrome 
of immune deficiency and autoimmunity. American journal of human genetics 90, 986 
(Jun 8, 2012). 
54. R. W. Cottingham, Jr., R. M. Idury, A. A. Schaffer, Faster sequential genetic linkage 
computations. American journal of human genetics 53, 252 (Jul, 1993). 
55. G. M. Lathrop, J. M. Lalouel, C. Julier, J. Ott, Strategies for multilocus linkage analysis 
in humans. Proceedings of the National Academy of Sciences of the United States of 
America 81, 3443 (Jun, 1984). 
56. A. A. Schaffer, S. K. Gupta, K. Shriram, R. W. Cottingham, Jr., Avoiding recomputation 
in linkage analysis. Human heredity 44, 225 (Jul-Aug, 1994). 
31 
Acknowledgements: 
We are deeply grateful to all affected individuals, their families and all healthy donor controls 
who participated in this study. We thank Dörte Thiel, Pavla Mrovecova, Katrin Hübscher, Mary 
Buchta, Hanna Haberstroh, Nadine Glaser, and Theresa Stauss for their excellent technical 
assistance. We thank Monika Schmidt and Ingrid Müller-Fleckenstein for generating patients’ T 
cell lines at the Institute of Clinical and Molecular Virology, University of Erlangen-Nürnberg. 
We thank Prof. Günter Finkenzeller for kindly providing primary skin fibroblasts of a healthy 
donor from the Plastic Surgery, Medical Center, University of Freiburg. We thank Dr. Michael 
Leipold for performing the CGH array (Supplement S3) at the Institute of Human Genetics, 
University of Freiburg. Sequencing for ChIP-Seq was conducted at the Genomics Core Facility 
of the European Molecular Biology Laboratories (EMBL). We thank the microarray unit of the 
DKFZ Genomics and Proteomics Core Facility for providing the Illumina Whole-Genome 
Expression Beadchips (Transcriptome study) and related services. 
Funding: Financial support for this research came from the German Ministry of Education and 
Research (BMBF, grant # 01E01303, sysINFLAME grants # 01ZX1306F and 01ZX1306A), 
from the Intramural Research Program of the National Institutes of Health, NLM, from the E-rare 
program of the European Commission EURO-CMC (01GM1502, ANR-14-RARE-0005-02), 
from the National Institutes of Health (R01AI127564), from the Jeffrey Modell Foundation 
Translational Research Program, from the German Center for Infection Research (DZIF), and 
from the Deutsche Forschungsgemeinschaft (DFG; SFB1160-IMPATH). The funding 
organizations had no role in study design, the collection, analysis and interpretation of data, the 
writing of the report, nor the decision to submit the paper for publication. The authors are 
responsible for the content of this research. JMH is a fellow of the MOTI-VATE graduate 
program of the Medical Faculty of Freiburg. 
32 
Author contributions: BG, AE, BZG, SSK initiated the project; AK, IL, ILR, SSK, BZG, AE 
took care of the patients; SFJ, JMH, MF, CB, MLW, JCN, MP, PF, CN, LY, JRR, NL, SWi, CG, 
BF, and BG designed and/or performed experiments and analyzed results; AB, SWi, KRE, CG, 
DP, SWei, and AAS performed genetic analysis; VB, AP and JLC created and provided reagents; 
SFJ, JMH, MF, CB, CN, JCN, and MP prepared the figures; SFJ, JMH, MF, CB, MLW, JCN, 
CN, and LY performed statistical analysis; and SFJ, JMH, MF, CB and BG drafted the paper. 
Competing interests: The authors declare no competing interests. 
Data and materials availability: Data accession number: ChIP-Seq: GSE107719, 
Transcriptome study: GSE109030.  
33 
FIGURES  
 
Fig. 1. Representative clinical and radiological manifestations in patients with homozygous 
ZNF341 nonsense mutations. 
(A) Severe eczema in patient B.II.4 on the upper arm and cubital. (B) Patient C.II.1 with eczema 
on the neck and a cold skin abscess in the lumbar region missing the typical inflammatory signs 
of rubor, calor, and dolor. (C) Oral thrush due to Candida in patient A.II.2. (D) Chest radiograph 
of patient A.II.1 showing bilateral pneumonia with positive air bronchogram, bronchiectasis, and 
pneumatoceles.   
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Fig. 2. Homozygous nonsense mutations in ZNF341 cause HIES with reduced Th17 cell 
numbers in patient PBMCs. 
(A-D) Pedigrees and genotypes with the nonsense mutated (mut) alleles g.32345116C>T 
(c.904C>T; p.Arg302*) for Families A-C and g.32349795C>T (c.1156C>T; p.Arg386*) for 
Family D. Heterozygous carriers are unaffected. Wt, wild-type. Circles, female; squares, male; 
filled symbols, affected individuals with HIES; open symbols, healthy members; slash, deceased 
individual; double horizontal lines, consanguinity; black dot, miscarriage. (E) Both mutations 
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predict premature termination of translation. (F) Flow cytometry of PBMCs demonstrate reduced 
Th17 cell counts on the basis of CD45RA
-
CCR6
+
CCR4
+
CXCR3
-
 of CD3
+
CD4
+
 in patients (n=6; 
triangles, Family A; squares, Family D) compared to healthy donor controls (HD; n=8; open 
circles) (left). In contrast to controls (n=11), patient PBMCs (n=6) fail to differentiate into IL-17
+
 
cells (CD3
+
CD4
+
CD45RO
+
) upon in vitro stimulation (d4) with Th17 polarizing cytokines IL-1β 
and IL-6 plus T cell activation/expansion (right). Significance was determined using Mann-
Whitney test. (G) ZNF341 is a 854 amino acids “zinc-finger-only” transcription factor with 
twelve C2H2 motifs (vertical boxes). R302* and R386* (arrows) delete zinc fingers 2-12 and 4-
12, respectively. A putative nuclear localization sequence (NLS; blue) is retained in the R386* 
mutant. Numbers indicate amino acid positions in NP 001269862.  
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Fig. 3. Reduced STAT3 expression in patient-derived cells.  
(A) Full length ZNF341 isoform 1 is undetectable in EBV cell lysates from patients with R302* 
(B.II.4, B.II.1) and R386* (D.II.4, D.II.2) mutations, respectively (upper panel). Slightly 
increased relative ZNF341 mRNA expression in patients´ PBMCs (lower panel; patients n=4; 
HD, n=8). Data from independent experiments were normalized to mean of relative expression in 
controls. (B) Reduced STAT3 mRNA expression in patient-derived cells. For PBMCs, data from 
independent experiments were normalized to mean of relative expression in controls (patients, 
n=4; HD, n=10). EBV cell lines: combined data from two independent experiments were 
normalized to relative expression of one control (patient A.II.1; HD, n=5). HVS transformed T 
cell line or primary skin fibroblasts (PSF) of patient A.II.3 compared to healthy donor (mean 
values and SD of two (HVS) or three (PSF) independent experiments). (C) Western blot and 
quantitative densitometry demonstrate reduced STAT3 expression in patient-derived PBMCs, 
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EBV cells, and PSF. Beta Actin and GAPDH were used as loading controls. TC, travel control; 
FC, freezing control. (D) ZNF341 knockout in Ramos cells by using CRISPR/Cas9 technology 
showed reduced STAT3 protein expression in clone 1 and 2 in comparison to wt Ramos cells. 
GAPDH was used as loading control.  
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Fig. 4. Patients´ primary T cells and EBV transformed B cell lines showed reduced Y705-
phosphorylation of STAT3. 
(A) Impaired IL-6 induced Y705-phosphorylation of STAT3 in patients´ PBMCs (gate CD3
+
) 
compared to healthy controls (HD: healthy donor; TC: travel control). (B) Reduced phospho-
STAT3 in IFN-α treated EBV cells from patients with R302* mutations (left). Bar graphs show 
SD of duplicates; MFI, mean fluorescence intensity. Representative histograms (middle) 
demonstrating reduced p-STAT3 in patient (solid line) compared to control (dotted line). Shaded 
area, unstimulated cells. Only marginal transient increase of p-STAT3 in patients 15 min post 
stimulation (right). Baseline p-STAT3 levels are reached within 150 min post stimulation. Mean 
values from independent experiments (HD1, 2 and B.II.4 (n≥3); B.II.1 (n=2)) are shown.  
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Fig. 5. ZNF341 binds to the STAT3 promoter. 
(A) Activation of a synthetic STAT3 promoter (with the -535/-33 upstream genomic sequence 
fused to CMV minimal promoter) driving a red fluorescence (tdTomato) reporter upon co-
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transfection with EGFP-tagged wild-type or mutant ZNF341 in HEK293T cells (48h). Scale bar 
100µM. (B) Relative reporter activity in two independent experiments in quadruplets. 
Significance and p-values were determined with Mann-Whitney test. (C) ChIP-Seq analysis of 
ZNF341, performed with distinct antibodies, on EBV-transformed B cells reveal 1658 ZNF341 
binding sites across various genomic regions and (D) show high tag densities on the STAT3 
promoter region (Chr17: 40,530,000-40,545,000, hg19 build; normalized tags). (E) Distribution 
of ZNF341 ChIP-Seq signal across the 1658 binding sites. Green, 36 super-binding sites (SBS) 
with >200 normalized tags; blue, remaining binding sites (RBS). (F) Normalized tags in SBS and 
RBS as a fraction of total. (G) Cis-regulatory sequences associated with ZNF341 occupancy. P 
values (italics) reflect the significance of motif occurrence. (H) A 30-nt cis-regulatory sequence 
associated with ZNF341 occupancy (P value as above) and with ZNF341 occupancy in SBS. (I) 
Representative confocal images of transfected HEK293T (48h) showing nuclear localization of 
EGFP-tagged wild-type ZNF341 and R386*, whereas R302* remains cytoplasmic. Scale bar, 10 
µM.  
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Supplementary Text 
Supplement S1. Case reports for Families A-D. 
Patients Family A-C 
Eight patients belong to three Arab families from a single village (total population ~14,000 
residents) in Israel. Some of these families immigrated from Sudan and Egypt in the 19th 
century. They settled in a swamp area, and until recent decades were isolated from other villages. 
This encouraged consanguineous marriages within the village. All our patients were known to be 
the offspring of consanguineous couples who were first cousins. 
Seven of the eight patients described here were initially diagnosed with severe atopic dermatitis, 
and later in life, with hyper-IgE syndrome. The immunologic work-up was mostly normal (n=7), 
except for highly elevated IgE in six patients. One patient with an inverted CD4/CD8 lymphocyte 
ratio had normal serum IgE levels. Mild intellectual disability was diagnosed in six children. 
FAMILY A includes three affected boys out of eight siblings:  
Patient A.II.1 is a 24-year-old man with severe dermatitis. He has had multiple admissions for 
the drainage of cold abscesses, several lung infections, and recurrent otitis. He also had 
bacteremia due to methicillin-resistant Staphylococcus aureus (MRSA). At the age of 17 years, 
he developed multifocal osteomyelitis involving the lumbar vertebrae and iliac bone. He receives 
continuous antibiotics and antihistamine treatment. The National Institutes of Health (NIH) 
hyper-IgE score (50) was 62. 
Patient A.II.2 is the brother of patient A.II.1, a 23-year-old male with chronic severe dermatitis, 
recurrent pneumonia, abscesses, and severe glossitis due to moniliasis. At the age of 12 years, he 
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was admitted with necrotizing pneumonia caused by MRSA. At age 22 years, the patient had a 
laminectomy for spinal stenosis at the level of C1/C2 which had caused spinal cord pressure. He 
is mentally challenged and lives in a boarding school for disabled children. The NIH-hyper-IgE 
score was 55. Serum IgE levels measured at 45,000 IU/ml. He is on continuous antibiotics 
treatment.  
Patient A.II.3, a brother of patient A.II.1 and A.II.2, is a 21-year-old male with chronic 
dermatitis, involving the legs and lower back, mild oral thrush, and abscesses, including one 
perianal abscess. He also is mentally challenged and lives together with his brother (patient 
A.II.2) in a boarding school for disabled children. He has been treated with continuous antibiotics 
and antihistamine medication. The NIH-hyper-IgE score was 58. His immunology testing 
revealed undetectable serum IgE levels (<4 IU/ml – upon repeated testing); IgG 2,400 mg/dl; IgA 
195 mg/dl; IgM 48 mg/dl. Lymphocyte subsets: CD3 83%; CD4 31%; CD8 46%; CD4/CD8-ratio 
0.67; CD20 15%; CD16 2%; CD56 2%. He had occasional eosinophilia of 15%-18% (AEC 700-
1100 mm
3
). 
FAMILY B includes three affected girls out of seven siblings. 
Patient B.II.1 is an 18-year-old girl with severe dermatitis involving the greater part of her body, 
including the limbs, back, and scalp. She was diagnosed with severe atopic dermatitis until 12 
years of age and later with hyper-IgE syndrome. She has intense pruritus and occasional skin 
abscesses, cutaneous infections with candida mainly on the scalp, and lung and ear infections. 
Her height is 150 cm. She has an intellectual disability and cannot read or write, except for 
signing her name. The parents attributed this to her poor school attendance caused by the 
immunological disease. She was admitted to the hospital several times for intravenous antibiotic 
treatment and she is a chronic carrier of MRSA. She receives continuous antibiotics and 
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antihistamine treatment. The NIH-hyper-IgE score was 33. Serum IgE values measured at 54,000 
IU/ml. 
Patient B.II.4 
This 12-year-old girl, a sister of patient B.II.1, has severe dermatitis, short stature, and 
intellectual disability. The dermatitis involves mainly the limbs and her back. She was diagnosed 
with atopic dermatitis until the age of 6 years, when she was diagnosed with hyper-IgE 
syndrome. She has chronic glossitis and oral thrush, and frequent ear infections. She has severe 
pruritus leading to bleeding lesions and occasional cutaneous candida infections mainly affecting 
the scalp. She has been admitted several times for intravenous antibiotic treatment and is a 
chronic MRSA carrier. Her height was 126 cm at the age of 12 years (-4SD for age); weight was 
30 kg (third percentile for age). She refused to attend school and cannot read or write. She 
receives continuous treatment with antibiotics and antihistamine medication. The NIH-hyper-IgE 
score was 30. Serum IgE measured at 29,000 IU/ml. 
Patient B.II.6 
This one-year-old girl is a sister of patients B.II.1 and B.II.4. At the age of 6 months, she was 
admitted to an intensive care unit with RSV bronchiolitis, pneumonia and oral thrush. In addition, 
she has mild dermatitis. Serum IgE at this time was 150 IU/ml (moderately elevated for age). The 
NIH-hyper-IgE score was 12.  
FAMILY C includes two affected boys out of six siblings.  
Patient C.II.1 is a 35-year-old man with chronic dermatitis and multiple recurrent cold 
abscesses. At birth, he was diagnosed with atrial septal defect and pulmonary stenosis, which 
were surgically corrected. He has had numerous admissions for the drainage of cold abscesses, 
including a giant subcutaneous skin tumor measuring 10 cm in diameter, which was a collection 
of pus. Abscess cultures grew coagulase-positive Staphylococcus aureus. He has an intellectual 
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disability, including difficulties in reading and writing, and no arithmetic knowledge. Serum IgE 
levels measured at 23,300 IU/ml. NIH- hyper-IgE score was 36.  
Patient C.II.6, the brother of patient C.II.1, is a 14-year-old boy with dry skin, and mild 
dermatitis involving the face, neck, and elbows. There were no infections except for otitis. He 
was never admitted to hospital. He has a mild developmental delay. He had transient IgA 
deficiency (IgA <6.5 mg/dl until the age of 10 years, and 220 mg/dl at the age of 13 years). He 
had occasional mild eosinophilia (AEC 1200/ml). Serum IgE levels measured at 7,640 IU/ml. 
The NIH-hyper-IgE score was 18. 
FAMILY D includes three affected females. 
Patient D.II.1 is a 36-year-old woman suffering from recurrent severe skin abscesses. She has 
hearing loss because of recurrent otitis, using a hearing aid device. She has been suffering from 
oral moniliasis since her infancy period. She had an iliopsoas abscess due to S. aureus.  
Salmonella enteritis was treated with ciprofloxacin at the age of 27 years. Nasopharyngeal 
carcinoma developed five years ago and the patient was cured by surgery, chemotherapy 
(cyclophosphamide, doxorubicin, vincristine), and radiotherapy. She developed papillary cell 
carcinoma of the left thyroid gland in 2017. She is currently being treated with IVIG every three 
weeks. Serum IgE levels measured at 13,916 IU/ml. Her NIH-hyper-IgE score was 60.  
Patient D.II.2, the sister of patient D.II.1, is a 30-year-old woman with chronic severe dermatitis 
and cold abscesses. She also has recurrent sinusitis. Serum IgE levels measured at 2,507 IU/ml. 
The NIH-hyper-IgE score was 28. 
Patient D.II.4, the sister of patients D.II.1 and D.II.2, is a 18-year-old female with chronic severe 
dermatitis and cold abscesses. In addition, she had recurrent otitis and sinusitis. Serum IgE levels 
measured at 1,825 IU/ml. Her NIH hyper-IgE score was 26.  
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Supplement S2. Defective B cell development and Th17 cell differentiation in HIES patients 
with ZNF341 nonsense mutations. 
Patients with ZNF341 mutations had normal CD19 lymphocyte counts, but an increased 
percentage of naïve B cells (IgD
+
CD27
-
), and reduced memory B cells (CD27
+
). This observation 
is in line with what has been observed in AD-HIES patients with dominant-negative mutations in 
STAT3 (51). Consistently, all memory B cell subpopulations including IgG
+
, IgA
+
, IgM
+
 were 
significantly reduced in the affected individuals (fig. S1A). Patients had normal counts for naïve 
and memory CD4
+
 and CD8
+
 T cells, and the CD4
+
 subsets called Th1, Th1*, and Th2 (fig. S1B). 
STAT3-dependent CCR6 expression (23) was significantly reduced in memory CD4
+
 T helper 
cells in patients (mean of CCR6
+
 16.6%, SD 6.35 for patients vs 32.7%, SD 5.54 for controls). 
Patient-derived PBMCs failed to differentiate into IL-17-producing CD4
+
 T cells using IL-1β and 
IL-6 in combination with T cell activation/expansion (Fig. 2F). In addition, we tested an 
alternative cytokine stimulation (IL-21 and TGF-β). Again patients´ PBMCs did not differentiate 
into IL-17-producing CD4
+
 T cells (fig. S1C). Thus, Th17 cell differentiation is affected in 
patients with ZNF341 mutations. In addition to the reduced percentage of IL-17
+
 T cells, patient- 
derived PBMCs also showed reduced numbers of IL-22
+
 T cells after stimulation with PMA/ 
ionomycin (fig. S1D).  
In addition to the elevated IgE, serum IgG was also high in all patients. In both patients B.II.1 
and C.II.1, specific antibody responses to vaccination showed a normal response to tetanus-
toxoid vaccination, but only a weak response to diphtheria toxin. Additionally, pneumococcal 
IgG titers after Pneumovax-23 vaccination were low for patient C.II.1 (table S1).  
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Supplement S3. Exclusion of mutations in STAT3 in the etiology of the HIES phenotype in 
Family A. 
In Family A, mutations in all coding exons and intron-exon boundaries of STAT3 were excluded 
by next generation sequencing (NGS) of patients A.II.1 and A.II.3. A wild-type STAT3 cDNA 
sequence was confirmed by Sanger sequencing of long range RT-PCR products derived from 
stimulated PBMCs of patient A.II.1 and the healthy sibling A.II.5. Mutations in the STAT3 
promoter region (chr20:40541608-40538416; GRCh37) were excluded by NGS or Sanger 
sequencing of genomic DNA. A large deletion in the STAT3 genomic region was excluded by a 
comparative genomic hybridization (CGH) array for patients A.II.1 and C.II.1.  
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Supplement S4. Identification of ZNF341 as an AR-HIES-associated gene in a linkage 
region on chromosome 20 by whole exome sequencing.  
To detect the underlying genetic defect in the index Family A, we first excluded mutations in 
known HIES- and candidiasis-related genes by targeted panel sequencing. Subsequently, a 
genome-wide homozygosity mapping was done by SNP chip for Family A. A single large 
interval consistent with linkage was identified on chromosome 20 (chr20). Homozygosity was 
confirmed and the boundaries were clarified with microsatellite markers yielding a maximal 
interval of 17.9 - 38.8 Mbp and a minimal interval of 19.8 - 36.4 Mbp (flanked by microsatellite 
markers D20S471 and D20S859). Some of the same microsatellites were genotyped in Family D, 
which was also consistent with linkage to chr20, but with a different disease-associated haplotype 
from that of Family A (suggesting a different mutation in the same chr20 region). 
Since the linkage region on chr20 contained hundreds of genes, we performed WES on two 
affected individuals and a healthy sibling of Family A. Within the minimal linkage interval of 
Family A, three sequence variants were detected with only the nonsense mutation in ZNF341 
affecting the coding sequence and being absent from dbSNP at that time.   
48 
Supplement S5. Expression of various ZNF341 mRNA variants in multiple cell lines and 
PBMCs.  
The expression pattern of ZNF341 transcripts (table S2) was evaluated in various cell types by 
reverse transcription (RT)-PCR with primer pair 1. A 574bp fragment, corresponding to 
transcript for isoform 1 and/or isoform 2 (ENST00000375200, ENST00000342427) was 
observed in all cell lines tested (Jurkat, HaCaT, EBV-transformed B cells, Ramos, HEK293T, 
HT1080, Colon205, HeLa, U2OS, JK6L, U266, and THP1). A weaker 377 bp fragment 
corresponding to transcript ENST00000497876 (predicted to undergo nonsense-mediated decay) 
and/or transcript for isoform 3 was obtained with Ramos, HEK293T and Colon205 cell lines (fig. 
S2A). Isoform 1 and/or isoform 2 were detected in PBMCs, monocytes, CD3
+
 T cells, and 
granulocytes, whereas transcript ENST00000497876 and/or isoform 3 were only present in 
monocytes (fig. S2B).  
49 
Supplement S6. Supplementary materials and methods. 
Antibodies for immunophenotyping 
For immunophenotyping, PBMCs were stained for cell surface markers with the following 
fluorochrome-conjugated antibodies: F(ab')2 Fragment Goat Anti-Human Serum IgA-FITC and 
F(ab')2 Fragment Goat Anti-Human IgG- Alexa Fluor 647 (both from JacksonImmunoResearch), 
CD27-PE (M-T271), CCR6-PE (11A9), CCR4-PeCy7 (1G1), CD3-APC-H7 (SK7), and 
CD45RA-PeCy7 (HI100) (all from BD Biosciences, Heidelberg, Germany), IgM-PerCp-Cy5.5 
(MHM-88), IgD-PeCy7 (IA6-2), CD19-APC-Cy7 (HIB19), CD27-BV421 (M-T271), CXCR3-
Alexa Flour 647 (G025H7), CCR7-BV421 (G043H7), CD25-Alexa Flour 647 (M-A251) and 
Zombie Aqua (all from BioLegend, London United Kingdom), and CD45RA-FITC (JS-83), 
CD4-PerCp-Cy5.5 (RPA-T4), and CD127-FITC (eBioRDR5) (all from eBioscience, Frankfurt, 
Germany).  
 
Intracellular IL-22 staining 
For intracellular IL-22 staining, fresh or frozen PBMCs were stimulated for 6 or 15 hours with 
50ng/ml PMA and 1µg/ml ionomycin (both from Sigma) in the presence of 5µg/ml Brefeldin A 
(BD Biosciences). Cells were stained for surface markers with anti-CD4 FITC (clone RPA-T4, 
BD Biosciences), anti-CD45RO PE-Cy7 (clone UCHL1, eBiosciences) and anti-CD3 APC H7 
(clone SK7, BD Bioscience), fixed and permeabilized using Cytofix kit (BD Biosciences). For 
intracellular staining anti-IL-22 PerCP-Cy5.5 (clone 2G12A41; isotype control IgG2a κ; 
Biolegend) and anti-IL-17 PE (Clone eBio64DEC17, eBioscience) were used. Fixable viability 
dye eFluor 506 (eBioscience, Frankfurt, Germany) was used according to the manufacturer´s 
instructions. 
Gating strategies for flow cytometry analysis are shown in figure S8-S11. 
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Genetic linkage analysis  
The genomic region containing the gene mutated in Family A was identified in 2007-2008 using 
a low-density SNP genotyping chip, microsatellite markers on chromosome 20 for fine mapping, 
and homozygosity mapping using previously described methods (52,53). For genetic linkage 
analysis, LOD scores were computed using FASTLINK (54-56) assuming a fully-penetrant 
recessive disease with a low-disease allele frequency of 0.001. 
 
Whole exome sequencing (WES)  
Genomic DNA was isolated from granulocyte pellets by alcohol precipitation according to 
standard procedures. WES was performed on gDNA of two patients and one healthy sibling of 
family A and an in-house bioinformatics WES data analysis pipeline was used for variant 
discovery. 
 
Next Generation Sequencing (NGS) and Sanger sequencing 
Sequencing data were generated by targeted panel re-sequencing. A customized gene panel 
containing all exons, including splice site regions of known HIES and CMC genes (including 
STAT3 and the STAT3 promoter region) and ZNF341 (for the identification of the mutation in 
family D), was designed with the help of Agilent’s web-based SureDesign application. Digestion 
of the DNA samples, hybridization of the restriction fragments, capturing of the target DNA, 
closing the circular fragments through a ligation reaction, and purification of the amplified target 
libraries was accomplished by following the manufacturer’s instructions (Agilent, Waldbronn, 
Germany). Enrichment was validated using a 2100 Bioanalyzer and samples were pooled in 
equimolar amounts for multiplexed sequencing using Illumina v2 kit reagents. After denaturation 
with NaOH, the libraries were diluted to a final concentration of 8-12pM and processed for 
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sequencing on an Illumina MiSeq following the manufacturer`s guidelines. Data were analyzed 
with Agilent’s SureCall software. 
The identified nonsense mutations in exon 6 and exon 8 of ZNF341 isoform 1 were confirmed by 
standard Sanger sequencing (GATC Konstanz, Germany) with the primers ex6-fw 5’-GTG CCA 
AAC CAG TGT GTG-3’, ex6-rs 5’-GTG CCA AAC CAG TGT GTG-3’ and ex8-fw 5’-ATG 
TTC TTT CTG GGC CTT CC-3` and ex8-rs 5’- CAG AGA GGT CAT GGG GTT TG-3`. The 
sequence of the STAT3 promoter was either analyzed by NGS covering the genomic region 
chr17:40,541,608-40,538,416 (GRCh37) or by Sanger sequencing (primers upon request), 
whereby a 19 bp sized region (GRCh37: chr17: 40,540,741- 40,540,759) was not analyzed. 
 
CGH Array  
Comparative genomic hybridization (GH) was performed by the lab of Dr. Michael Leipold at the 
Institute of Human Genetics, Faculty of Medicine, University of Freiburg, by using a 
CytoSureConstitutional (DDD) v3 180K-Chip from Oxford Gene Technology (ogt). 
 
Transcriptome study  
Expression Profiling on HumanHT-12 v4 Expression BeadChip (Illumina) was performed at the 
microarray unit of the DKFZ, Genomics and Proteomics Core Facility, Heidelberg, Germany, 
following manufacturer's protocols. 
With the Illumina TotalPrep RNA Amplification Kit (life technologies) single-stranded cRNA 
(labelled with biotin) was generated from input amounts of 60ng total RNA. For hybridization 
the “Standard Illumina Hybridization Protocol" Part # 11322355 (Whole-Genome Gene 
Expression Direct Hybridization Assay Guide) was followed: 500 ng of cRNA were hybridized 
for 17 hours at 58°C on the microarray. After staining with Cy3-Streptavidin against biotin the 
52 
microarray was scanned with Illumina iScan-Scanner according to "Standard Illumina Scanning 
Protocol" Part # 11322355 (Whole-Genome Gene Expression Direct Hybridization Assay 
Guide). Raw data was quantile normalized with R and Bioconductor package "preprocessCore".  
As test for significance the student’s t-test was used on the bead expression values of each sample 
and for comparing the two samples, additionally the Benjamini-Hochberg correction was applied. 
 
Western blotting  
Fresh or frozen PBMCs, EBV transformed B cells, PSF, or transfected HEK293T cells were 
washed with PBS, pelleted and lysed in lysis buffer (50mM Tris-HCl, pH 8.0, 150 mM NaCl, 
0.1% SDS, 0.5% sodium deoxycholate, 1mM EDTA, 1% NP40), containing EDTA-free Protease 
Inhibitor Cocktail (Roche) and Phosphatase Inhibitor Cocktail 2 and 3 (Sigma-Aldrich). Protein 
concentrations were determined with the Pierce BCA Protein Assay Kit (Thermo Scientific). 
Protein lysates were separated by 10% SDS-PAGE gels and transferred to PVDF membranes, 
followed by 5% nonfat milk (Bio-Rad Lab) blocking. Membranes were probed with primary 
antibodies separately for STAT3 (MAB1799; R&D Systems), ZNF341 (monoclonal customized 
antibody or polyclonal Atlas Antibody HPA024607), GAPDH (G9295; Sigma), or beta-actin 
(NB 600-532; Novus Biologicals), followed by HRP-conjugated anti-mouse/rabbit secondary 
antibodies (sc-2096 and sc-2077; Santa Cruz Biotech, Heidelberg Germany). Signals were 
detected with ECL substrates LumiGLO or SignalFire Plus (Cell Signalling) on a Fusion Fx7 
imaging system (PeqLab, Erlangen Germany) and quantified with Image J software. 
 
Primers for ChIP-Seq 
ChIP primers were as follow STAT3: 5’-GGA GAG CAG CTA GGA GAA AGG-3’ and 5’- 
CAG GAC ATT CCG GTC ATC TT-3’; UNTR5: 5’-CTG TAC CTG GGG TTC ATT CAT T-3’ 
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and 5’-CAG TAA GCC GTT CAC TCT CAC A-3’; ActB: 5’-AGA AGT CGC AGG ACC ACA 
CT-3’ and 5’-CAG CTC CAG GGT AAA AGG TG-3’. 
 
Isolation of monocytes, granulocytes and CD3
+
 T cells 
CD14
+
 Monocytes were isolated with the CD14 MicroBeads human kit from MACS Miltenyi 
Biotec according to the manufacturer’s protocol. Polymorphprep was used for isolation of 
granulocytes by density gradient centrifugation. CD3
+
 T cells were isolated by fluorescence-
activated cell sorting with the antibody CD3-FITC (UCHT1) from BD Biosciences.  
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Fig. S1. B and T cell subsets in patient-derived and healthy donor PBMCs. 
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(A) Flow cytometry of PBMCs from healthy donors (HD) and patients with homozygous 
ZNF341 nonsense mutations demonstrates increased numbers of naïve IgD
+
 CD19-positive B 
cells but a reduced naïve class switched (IgM
-
IgD
-
) subpopulation (upper panels) as well as 
reduced memory B cells (CD27
+
) and IgA/IgG/IgM-positive class switched memory B cells 
(lower panels). (B) In patients with homozygous ZNF341 mutations the CD3-positive T cells had 
normal subpopulations of naïve CD4
+
 or CD8
+
 (upper panels) and memory CD4
+
 (CD45RA
-
), 
slightly reduced central memory CD4
+
 cells (CD45RA
-
 CCR7
+
), and normal memory CD8
+
 
(CD45RA
-
) and Tregs (CD45RA
-
CD127
low
CD25
+
) (middle panels). The subpopulations of 
CD3
+
CD4
+
 lymphocytes showed normal distributions of Th1 (CD45RA
-
CCR6
-
CCR4
-
CXCR3
+
), 
Th1* (CD45RA
-
CCR6
+
CCR4
-
CXCR3
+
) and Th2 (CD45RA
-
CCR6
-
CCR4
+
CXCR3
-
), and weakly 
reduced CCR6
+ 
memory cells (CCR6
+
CD3
+
CD4
+
CD45RA
- 
T cells) (lower panels). (HD, n=8, 
n=7 for Tregs; patients n=6, n=5 for Tregs). (C) Flow cytometric analyses of PBMCs 
demonstrate impaired Th17 differentiation upon in vitro stimulation (d4) with Th17 polarizing 
cytokines TGF-β and IL-21 in combination with T cell activation/expansion (HD, n=2, patient 
n=3). (D) Reduced percentages of IL-22
+
 T cells upon in vitro stimulation with PMA/ionomycin 
(HD, n=3; patient n=3, n=2 for 15h). Open circles, healthy donor controls (HD); triangles, 
patients with R302* mutation; squares, patients with R386* mutation. Significance was 
determined using Mann-Whitney test, p values are indicated.  
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Fig. S2. Ubiquitous expression of ZNF341 mRNA in various cell types. 
(A) ZNF341 transcripts are detectable by reverse transcription (RT)-PCR in all cell lines and cell 
types tested (as indicated), including healthy donor-derived PBMCs and EBV-transformed B 
cells. (B) ZNF341 transcripts are detectable in HD PBMCs, monocytes, CD3
+
 T cells and 
granulocytes. No RT samples, no template samples (water) and genomic DNA (gDNA) served as 
controls. DNA size markers are indicated. For primer specification, see the legend of Table S2.  
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Fig. S3. No association of the genomic region 20q11.22 spanning the ZNF341 locus with 
atopy.  
(top panel) Regional association plot (from EAGLE Meta-analysis) of the locus 20q11.22 
depicting the -log10 P-values with regard to the physical location of each marker. The purple 
diamond indicates the variant with the lowest p-value (rs111686767; p=0.0018). The color of the 
filled dots (see color code) corresponds to the strength of linkage disequilibrium (r2) with 
rs111686767. Blue line: recombination intensity (cM/Mb). (bottom panel) Positions and gene 
annotations are according to NCBI’s build 37 (hg19).  
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Fig. S4. Ectopic expression of ZNF341 variants in HEK293T cells. 
(A) The relative STAT3 mRNA expression (STAT3/GUSB) was two-fold increased 48 hours post 
transfection of EGFP-fused wild-type ZNF341 in HEK293T cells but remained unchanged with 
the truncated ZNF341-R302* mutant variant. Bars represent mean +/-SD of three independent 
transfection and RT-qPCR experiments. Values were normalized to the empty vector control. (B) 
Schematic drawing of wild-type and R302* or R386* mutant EGFP-fused (C1) and non-fused 
(N1) ZNF341 expression constructs with expected protein sizes. (C) HEK293T cells 48h post 
transfection with the indicated expression vectors were analyzed by Western blotting with the 
polyclonal anti ZNF341 antibody. Empty vectors and untransfected HEK293T cells served as 
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controls. Mutant variants gained higher expression levels than wild-type proteins. Representative 
results are shown (n=3 for R302* and n=1 for R386*).  
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Fig. S5. Ectopically expressed wild-type ZNF341 binds to the STAT3 promoter leading to 
transcriptional activation. 
Synthetic promoters with upstream genomic sequences fused to the CMV minimal promoter 
driving a red fluorescence (tdTomato) reporter were co-transfected with EGFP-ZNF341 variants 
in HEK293T cells. (A) STAT3 promoters (-997/-33; -535/-33 or -476/-33 relative to the 
transcription start) are activated by ZNF341 wild-type whereas the CMV minimal promoter alone 
(empty reporter vector) and RORC- and IL17A- promoter fusion constructs are silent. (B) Robust 
reporter activity (upper panel) with the wild-type ZNF341 and the much higher expressed R386* 
variant and marginally increased activation with the R302* mutant compared to baseline (empty 
expression vector). EGFP fluorescence intensities (lower panel) indicate expression levels of the 
indicated transfected constructs. Representative results are shown. (C) Reporter assays (n=4) 
were performed in 48 well plates in quadruplets and relative reporter activity was evaluated with 
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a Fluorospot reader at variable time points (48h/72h/96h; n=2 each) as indicated. Significance 
was determined using Mann-Whitney test, p values are indicated.  
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Fig. S6. Occupancy by ZNF341 across the STAT3 promoter as determined by ChIP.  
(A) Quantification of tag counts obtained with ZNF341 monoclonal or polyclonal antibody in 
ZNF341 peaks. Pearson correlation test (r
2
 0.83) indicated a high correlation. (B) ChIP was 
performed in EBV cell lines derived from two healthy donors using polyclonal antibody against 
ZNF341. For HD1, data are representative of two independent experiments. (C) ChIP was 
performed as in B using one healthy donor and patient (B.II.4). Data are representative of two 
independent experiments. IgG was used as control and the ACTB promoter and a 
transcriptionally inactive region (UNTR) served as target controls.  
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Fig. S7. ZNF341 R386* shows reduced binding to the STAT3 promoter.  
(A+B) GFP-ChIP assay in HEK293T cells overexpressing EGFP-tagged ZNF341 proteins (wt, 
R386*, R302*) or EGFP only. Binding at STAT3 promoter (STAT3) is shown as normalized to 
Input (A) or to ACTB (B). (C) Percentage of EGFP-positive cells after transfection with ZNF341 
variants as determined by flow cytometry. (D) MFI as a measure of EGFP-tagged ZNF341 
protein expression (n= 2).  
64 
Fig. S8. Flow cytometry gating strategy for in vitro Th17 cell differentiation assay.  
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Fig. S9. Flow cytometry gating strategy for Y705-phosphorylation of STAT3.  
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Fig. S10. Flow cytometry gating strategy for immune phenotyping of PBMCs. 
(A) B cell panel, (B) T helper cell staining and (C) Regulatory T cell panel.  
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Fig. S11. Flow cytometry gating strategy for IL22
+
 T cells. 
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Patient ID A.II.1 A.II.2 A.II.3 B.II.1 B.II.4 B.II.6 C.II.1 C.II.6 D.II.1 D.II.2 D.II.4 
Year of birth 1992 1993 1994 1998 2004 2015 1981 2002 1981 1986 1999 
Sex m m m f f f m m f f f 
Age of onset 2-5 years 2-5 years 2-5 years 1 year 1 year 6 months unknown unknown <1 year 2-5 years unknown 
Age at 
evaluation 
[years] 
24 23 22 17 10 6 months 17 13 22  30 17 
Ethnicity 
Israeli-
Arab 
Israeli-
Arab 
Israeli-
Arab 
Israeli-
Arab 
Israeli-
Arab 
Israeli-
Arab 
Israeli-
Arab 
Israeli-
Arab 
Turkish Turkish Turkish 
Country of 
Origin 
Israel Israel Israel Israel Israel Israel Israel Israel Turkey Turkey Turkey 
Consanguinity yes yes yes yes yes yes yes yes yes yes yes 
First clinical 
symptom 
Atopic 
dermatitis 
Atopic 
dermatitis 
Atopic 
dermatitis 
Atopic 
dermatitis 
Atopic 
dermatitis 
Recurrent 
infections 
Atopic 
dermatitis 
Atopic 
dermatitis 
unknown unknown unknown 
Current 
diagnosis 
HIES HIES HIES HIES HIES 
Mild 
dermatitis 
HIES HIES HIES HIES HIES 
NIH Score  
46  
(aged 13) 
62  
(aged 24) 
41  
(aged 15) 
55  
(aged 23) 
16  
(aged 14) 
58  
(aged 22) 
33 30 12 36 18 60 
22  
(aged 14) 
28  
(aged 30) 
26  
Clinical 
Features             
Respiratory 
tract 
involvement 
yes yes yes yes yes yes yes yes yes yes yes 
Upper 
respiratory 
infections 
(sinusitis/otitis) 
1-2 / year 1-2 / year 1-2 / year 1-4/ year 1-2/ year no unknown otitis  >8/ year >6/ year >3/year 
Lower 
respiratory 
>6 >3 >3 unknown unknown 
1, 
RSC 
unknown unknown 
>3 
(Proteus 
no 1  
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infections 
(pneumonias) 
bronchioli
tis 
mirabilis, 
Staph.aur
eus) 
Other 
pulmonary 
features 
Bronchiec
tasis, 
Pneumato
celes 
Bronchiec
tasis 
Bronchiec
tasis 
no no unknown no no 
Asthma, 
Bronchiec
tasis 
unknown unknown 
Skin 
involvement 
yes yes yes yes yes unknown 
yes, 
severe 
yes, 
severe 
yes yes yes 
Skin infection yes yes yes yes yes no yes yes yes unknown unknown 
Abscesses 
(number) 
>20 >5 >2 >6 >4 no >20 >3 >4 3-4 >4 
 Location 
dissemina
ted 
dissemina
ted 
dissemina
ted 
dissemina
ted 
dissemina
ted 
not 
applicable 
dissemina
ted 
dissemina
ted 
neck and 
iliopsoas  
dissemina
ted 
dissemina
ted 
 Germ 
Staph. 
Aureus 
Staph. 
aureus 
Staph. 
Aureus 
Staph. 
Aureus 
Staph. 
Aureus 
not 
applicable 
Staph. 
aureus 
Staph. 
aureus 
Staph. 
aureus 
unknown unknown 
Eczema ↑↑↑ ↑↑↑ ↑↑ ↑↑↑ ↑↑ mild ↑ ↑ ↑↑↑ ↑↑↑ ↑↑↑ 
Candidiasis fingernail 
oral, 
glossitis 
oral, 
fingernail 
yes, scalp oral, scalp oral no no ear  no no 
Viral 
infections 
no no no no no no no no unknown unknown unknown 
Molluscum 
contagiosum 
no no no no no no no no no no no 
Herpes no no no no no no no no 
local 
herpes 
simplex 
no no 
Warts no no no no no no no no no no no 
Cutaneous 
vasculitis 
no no no no no no no no no  no no 
Newborn rash unknown unknown unknown unknown unknown no unknown unknown yes no no 
Dry skin yes yes yes yes yes yes yes yes no no no 
Psoriasis no no no no no no no no no no no 
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Allopecia/ 
Hair loss 
no no no yes no no no no no no no 
Others unknown unknown unknown unknown unknown unknown unknown unknown 
iliopsoas 
abscess  
unknown unknown 
Dentition 
affected 
yes yes yes unknown yes unknown unknown unknown no no no 
Retained 
primary teeth 
yes  
(2 
retained 
teeth) 
yes 
(2 
retained 
teeth) 
yes  
(2 
retained 
teeth) 
unknown yes unknown unknown unknown no no no 
Fractures  
(with minimal 
trauma) 
no no no no no no yes  no no no no 
Scoliosis yes no no no no no no no no no no 
Hyperexten-
sibility of 
joints 
no no no no no no no no no no no 
Facial 
abnormalities 
Increased 
nose 
width, 
high 
palate 
Increased 
nose 
width, 
high 
palate 
Increased 
nose 
width 
no 
Increased 
nose 
width 
unknown 
Increased 
nose 
width 
Increased 
nose 
width 
High 
palate, 
macrognat
ic, narrow 
foreland, 
maxillary 
hypoplasi
a 
High 
palate, 
macrognat
ic, narrow 
foreland 
High 
palate 
Other 
Infections 
Osteomye
litis, 
MRSA 
MRSA MRSA MRSA MRSA unknown unknown unknown unknown unknown unknown 
Autoimmunity no no no no no no no no no  no  no  
Allergies no no no no no no no no no no no 
Lymphoprolife
ration  
no no no no no no no no no no no 
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Splenomegaly/ 
Hepatomegaly 
no no no no no no no no no no no 
Lymphadenop
athy  
no no no yes yes no no no no no no 
Lymphocytic 
organ 
infiltration  
no no no unknown unknown no no no no no no 
Growth 
retardation 
no no no no 
short 
stature 
(126 cm 
aged 12 = 
-4SD) 
unknown unknown unknown 
size: 10
th
 
to 25th 
percentile; 
weight: 
3
rd
 to 10
th
 
percentile 
no no 
Mental delay unknown yes yes yes yes no yes yes yes (mild) no no 
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Immunoglobul
in Levels 
(date) 
unknown unknown unknown unknown unknown unknown unknown unknown 
07/04/201
6 
07/04/201
6 
07/04/201
6 
IgG [mg/dl] 1,710 2,980 2,420 2,600 2,420 unknown 2,360 unknown 1,680    1,580  1,460  
IgG [mg/dl]  
Subclasses 
not done 
IgG1= 
1,930 
IgG2= 
220 
IgG3= 72 
IgG4= 42 
IgG1= 
1,360 
IgG2= 
435 
IgG3= 47 
IgG4= 63 
IgG1= 
1,640 
IgG2= 
206 
IgG3= 50 
IgG4= 
1,010 
IgG1= 
1,300 
IgG2= 
400 
IgG3= 30 
IgG4= 
450 
not done 
IgG1= 
1,530 
IgG2= 
240 
IgG3= 84 
IgG4= 67 
not done 
IgG1= 
1,670  
IgG2= 
186 
IgG3= 54  
IgG4= 
331 
IgG1= 
1,180 
IgG2= 
121 
IgG3= 
68.8 
IgG4= 
330 
IgG1= 
1,090 
IgG2= 
186 
IgG3= 
45.3 
IgG4= 
519 
IgM [mg/dl]  115 62 64 150 unknown unknown 73 unknown 70.5 54.8 85.3 
IgA [mg/dl]  170 190 193 150 unknown unknown 98 unknown 179 371 203 
IgE [IU/ml] 
33,200 
(2008: 
210,000) 
44,900 
(2008: 
10,000) 
< 4         
 (2008: 
15,000) 
54,360 28,900 
150 
(moderate
ly 
elevated 
for age) 
23,300 
11,000 
and 7,640 
13,916 2,507 1,825 
polyclonal yes yes yes yes yes unknown unknown unknown unknown unknown unknown 
Specific 
Antibody 
responses; 
Serology/Virol
ogy 
           
Tetanus IgG not done not done not done yes not done not done yes not done unknown unknown unknown 
Diphtheria 
IgG 
not done not done not done weak not done not done weak not done unknown unknown unknown 
Pneumococcal 
IgG 
not done not done not done not done not done not done weak not done unknown unknown unknown 
pneumovax 23 
vaccination 
not done not done not done not done not done not done yes not done unknown unknown unknown 
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CMV IgG/IgM not done not done not done negative not done not done not done not done 
IgG-
positive 
IgM-
negative 
no 
IgM-
negative 
EBV IgG/IgM not done not done not done 
IgG-
positive 
IgM-
negative 
negative not done not done not done unknown no no 
Others no no Polio ↑ 
Pertussis-
negative 
Pertussis-
negative 
no no no no no no 
Parameters of 
acute phase 
response 
           
Infection 
status at time 
of evaluation 
not done 
steady 
state 
steady 
state 
steady 
state 
steady 
state 
steady 
state 
not done not done 
steady 
state 
(pneumon
ia) 
not done not done 
CRP [mg/l] not done 7 <3 <3 <3 5 not done not done 
4.5 
(160) 
not done not done 
Ferritin 
[ng/ml] 
not done 93 42 46 16 17 not done not done  not done not done 
SAA [mg/l] not done not done not done not done not done not done not done not done 9.34 not done not done 
Mendel 
Mantoux 
(PPD) 
not done not done not done not done not done not done not done not done negative not done not done 
Blood counts            
RBC [cells/µl] 5 mio 4.9 mio 4.8 mio 4.9 mio 4.7 mio unknown 5.4 mio unknown 4.5 mio 4.6 mio 5 mio 
WBC 
[cells/ml] 
10,900 7,800  4,700 8,500 6,640 unknown 3,900 unknown 5,250 4,130 4,680 
ANC [cells/ml] 5,700 1,500 1,100 5,500 2,200 unknown 1,900 unknown 1,890 2,060 2,770 
Platelet count 
[cells/ml] 
460,000 245,000 290,000 270,000 286,000 unknown 240,000 unknown 282,000 374,000 336,000 
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Lymphocytes 
absolute 
[cells/µl] 
2,200 1,900 1,900 1,400 3,100 unknown 1,100 unknown 2,060 3,110 3,340 
Eosinophils 
[cells/µl] 
2,200 900 
1,000 
(700-
1,100;15-
18%) 
700 900 unknown 300 1,200 290 220 700 
CD3+  
[cells/µl] and 
[%]  
not done 
1,640 
(86%) 
1,665 
(83%) 
1,544 
(72%) 
2,476 
(42%) 
not done not done not done 
2,250.4 
(84.8%) 
84% unknown 
CD3+CD4+ T 
cells [cells/µl] 
and [%]  
not done 
900 
(47%) 
618 
(31%) 
786 
(39%) 
1,300 
(42%) 
not done not done not done 
530.86 
(19.4%) 
35.5 % unknown 
CD3+CD8+ T 
cells [cells/µl] 
and [%] 
not done 
676 
(36%) 
928 
(46%) 
648 
(32%) 
1,026 
(33%) 
not done not done not done 
1,651 
(64.1%) 
41% unknown 
CD4/CD8 ratio not done 1.32 0.67 1.2 1.2 not done not done not done 0.3 0.87 unknown 
CD19+  
[cells/µl] and 
[%] 
not done 
170 
(9.5%) 
308 
(15.4%) 
352 
(17.6%) 
490 
(15.8%) 
not done not done not done 
198.12  
(12.9%) 
8.5% unknown 
CD56+CD16+ 
[cells/µl] and 
[%] 
not done 
76  
(4%) 
42  
(2.1%) 
20  
(4.3%) 
108 
(3.5%) 
not done not done not done 
55.8 
(1.3%) 
7.7% unknown 
Treatment            
Antifungals no 
Fluconazo
le 
no 
Fluconazo
le 
Fluconazo
le 
no no no no no no 
Antibiotics  yes yes yes yes yes no yes no yes no no 
     
Prophylactic    
antibiotics 
AUGME
NTIN  
(amoxicill
in/ 
clavulanat
AUGME
NTIN  
(amoxicill
in/ 
clavulanat
AUGME
NTIN  
(amoxicill
in/ 
clavulanat
AUGME
NTIN  
(amoxicill
in/ 
clavulanat
AUGME
NTIN  
(amoxicill
in/ 
clavulanat
no 
AUGME
NTIN  
(amoxicill
in/ 
clavulanat
no 
Trimethop
rim/sulfa
methoxaz
ole 
5mg/kg/d
no no 
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e) e) 
RESPRI
M 
(trimethop
rim/sulfa
methoxaz
ole) 
e) 
RESPRI
M 
(trimethop
rim/sulfa
methoxaz
ole) 
e) e) 
RESPRI
M 
(trimethop
rim/sulfa
methoxaz
ole) 
e) ay on 3 
days a 
week 
Immunglobuli
n treatment 
(s.c./i.v.) 
no no no no no no no no 
IVIG 25 
gr (454 
mg/kg),  
in 3 
weeks 
intervals  
no no 
Bisphosphonat
es 
no no no no no no no no no no no 
Others 
antihistam
ine 
treatment 
no 
antihistam
ine 
treatment 
antihistam
ine 
treatment 
antihistam
ine 
treatment 
no no no 
IVIG 
since 
2008 
no no 
unknown (data not available), ↑ indicating the degree of affection 
Table S1. Clinical and immunological phenotype of HIES patients with ZNF341 mutations.   
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Ensemble  
Transcript 
Biotype 
Ensembl  
exons 
Uni 
Prot 
NCBI  
Ref Seq 
NCBI 
Protein 
Protein Size  RT-PCR product 
with primer pair 1 
[bp] [aa] [kDa] 
ENST000
00375200 
Protein 
coding 
15 
Q9
BY
N7-
1 
NM_00
1282933 
Isoform 1 
NP_00126
9862 
854 92.7 574 
ENST000
00342427 
Protein 
coding 
15 
Q9
BY
N7-
2 
NM_03
2819 
Isoform 2 
NP_11620
8 
847 92 574 
▬ ▬ ▬ ▬ 
NM_00
1282935 
Isoform 3 
NP_00126
9864 
764 83.6 377 
ENST000
00483118 
Nonsense 
mediated 
decay 
14 
E9P
N62 
 
Isoform 4 
(none) 
604 64.2 no amplicon 
ENST000
00497876 
Nonsense 
mediated 
decay 
14 
E9P
QQ
0 
▬ ▬ 72 7.4 377 
ENST000
00493497 
Retained 
intron 
3 ▬ ▬ ▬ 
no 
protein 
 no amplicon 
Table S2. ZNF341 encodes three protein coding isoforms.  
Several minor variants with unknown relevance are indicated. Primer pair 1 (fw 5’-CTC CCA 
CAA TGC TCG CGT AG-3’ and rv 5’-ACG GAA TGC ATG TTC AGG CTG-3’) spans exon 3 
(of isoform 1 and 2) which is not included in transcript ENST00000497876 and isoform 3 and 
thus produces two different products.  
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Gene Fold change 
IL10 1.71 
ATF3 1.64 
FOXP3 1.19 
SMAD3 1.17 
IL5 1.16 
ATF4 1.14 
IL22 1.07 
IL23R 1.07 
IL17A 1.06 
RORC 1.05 
SPTBN1 1.05 
STAT5B 1.03 
STATH 1.01 
IL21 0.99 
STAT2 0.97 
IL23A 0.96 
IL21R 0.95 
EGF 0.94 
ZNF341 0.93 
SOCS3 0.92 
CTLA4 0.9 
STAT4 0.88 
ZNF382 0.86 
STAT5A 0.85 
HMGB1 0.83 
STAT6 0.81 
IL6 0.73 
STAT1 0.65 
KAT6A 0.63 
JAK1 0.61 
STAT3 0.51 
Table S3. Transcriptome Analysis of patient A.II.1 with gene-specific fold changes in 
comparison to healthy sibling A.II.5.  
Only genes relevant to the main document or for immunodeficiencies are listed. 
 
